Evidence map›Paper›PMID 19692539›Full record

ArticleInternational immunology2009

Lactoferrin modulation of BCG-infected dendritic cell functions.

Shen-An Hwang, Jeffrey K Actor

Open access · greenAbstract read
In one paragraph

Article in International immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Lactoferrin and its digestive peptides induce interferon-α production and activate plasmacytoid dendritic cells ex vivo.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Journal of immunology research · 2018
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. CHO expressed recombinant human lactoferrin as an adjuvant for BCG.International journal of immunopathology and pharmacology · 2015
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Shen-An HwangDepartment of Pathology and Laboratory Medicine, Medical School, University of Texas-Houston Medical School, Houston, TX 77030, USA.
Jeffrey K Actor
The University of Texas Health Science Center at Houston · US

Funding

Lactoferrin as an Adjuvant for Cellular ImmunityR42AI051050 · NIAID · PHARMAREVIEW CORPORATION · PI ACTOR, JEFFREY K · 2005 to 2010
$4.1M
Lactoferrin for Immunomodulation of Systemic Inflammatory Response SyndromeR41GM079810 · NIGMS · PHARMAREVIEW CORPORATION · PI ACTOR, JEFFREY K · 2007 to 2008
$298k
NIAID NIH HHS R42-AI051050-03NIGMS NIH HHS 1R41GM079810-01
6 · The paper itself

Abstract

Lactoferrin, an 80-kDa iron-binding protein with immune modulating properties, is a unique adjuvant component able to enhance efficacy of the existing Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine to protect against murine model of tuberculosis. Although identified as having effects on macrophage presentation events, lactoferrin's capability to modulate dendritic cells (DCs) function when loaded with BCG antigens has not been previously recognized. In this study, the potential of lactoferrin to modulate surface expression of MHC II, CD80, CD86 and CD40 from bone marrow-derived dendritic cells (BMDCs) was examined. Generally, lactoferrin decreased pro-inflammatory cytokines [tumor necrosis factor (TNF)-alpha, IL-6 and IL-12p40] and chemokines [macrophage inflammatory protein (MIP)-1alpha and MIP-2] and increased regulatory cytokine, transforming growth factor-beta1 and a T-cell chemotatic factor, monocyte chemotactic protein-1, from uninfected or BCG-infected BMDCs. Culturing BCG-infected BMDCs with lactoferrin also enhanced their ability to respond to IFN-gamma activation through up-regulation of maturation markers: MHC I, MHC II and the ratio of CD86:CD80 surface expression. Furthermore, lactoferrin-exposed BCG-infected DCs increased stimulation of BCG-specific CD3(+)CD4(+) splenocytes, as defined by increasing IFN-gamma production. Finally, BCG-/lactoferrin-vaccinated mice possessed an increased pool of BCG antigen-specific IFN-gamma producing CD3(+)CD4(+)CD62L(-) splenocytes. These studies suggest a mechanism in which lactoferrin may exert adjuvant activity by enhancing DC function to promote generation of antigen-specific T cells.

Indexed as

Adjuvants, ImmunologicAnimalsB7-1 AntigenB7-2 AntigenBCG VaccineCD40 AntigensCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCytokinesDendritic CellsDisease Models, AnimalFemaleHistocompatibility Antigens Class IILactoferrinMiceMice, Inbred C57BLAdjuvants, ImmunologicB7-1 AntigenB7-2 AntigenBCG VaccineCD40 AntigensCytokinesHistocompatibility Antigens Class IILactoferrin

Identifiers

PMID19692539
PMCPMC2750247
OpenAlexW2112933315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.